Acute renal failure associated with carcinoid crisis

Parry, R. G.; Glover, S. C.; Dudley, Christopher

doi:10.1093/oxfordjournals.ndt.a027221

Cited by 6 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Ahlman et al, 1987;Marsh et al, 1987;Roy et al, 1987;Ahlman et al, 1988a;Ockert and White, 1988;Darby et al, 1990;Debas and Mulvihill, 1994;Deguchi et al, 1994;Parry et al, 1996;Pekarek et al, 1997;Balestrero et al, 2000;Janssen et al, 2000;Kharrat and Taubin, 2003;Zimmer et al, 2003;Koopmans et al, 2005;Davi et al, 2006;Majeed et al, 2007;Papadogias et al, 2007;De Keizer et al, 2008;McPherson et al, 2009;Sinha et al, 2009;Yazbek-Karam et al, 2009;Fujie et al, 2010;Morrisroe et al, 2012;Raikhelkar et al, 2012;Shah et al, 2012;Massimino et al, 2013;van Diepen et al, 2013) The prophylactic usage of SSTA was diverse between different studies varying from long acting SSTA to continuous somatostatin infusion. Of the 28 patients with known demographic information, 17 cases (60.7%) were men and 11 cases (39.3%) were women.…”

Section: Resultsmentioning

confidence: 99%

“…(Modlin et al, 2010) Rarely, acute renal failure, acute severe pulmonary oedema and coronary artery spasm have also reported to be associated with carcinoid crisis. (Parry et al, 1996;Erdem et al, 2010;Shah et al, 2012) The incidence of carcinoid crisis varies between different settings of outbreak. During abdominal operations, the incidence of carcinoid crisis was as high as 24% according to a recent study.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/ surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…As previously shown in Table 1, not only direct manipulations of tumor mass, such as bronchoscopy [16,20], liver biopsy [13,16] or locoregional treatments [18,21], but also other kinds of tumor solicitations, such as the induction of anesthesia [14] or the infusion of radiotracers [17], can contribute to the rapid onset of CC. In addition, following the results of the NETTER-1 trial, the increasing use of peptide radionuclide therapy (PRRT) has led to a rise in CC due to tumor lysis [22], most frequently after the first cycle of treatment, and the main risk factors include large tumor burden, liver metastases, previous CS, carcinoid heart disease, advanced patient age, high chromogranin A levels and high 5-HIAA levels.…”

Section: Clinical Definition and Presentationmentioning

confidence: 99%

Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency

Bardasi

Benatti

Luppi

et al. 2022

Cancers

View full text Add to dashboard Cite

Carcinoid Crisis represents a rare and extremely dangerous manifestation that can occur in patients with Neuroendocrine Tumors (NETs). It is characterized by a sudden onset of hemodynamic instability, sometimes associated with the classical symptoms of carcinoid syndrome, such as bronchospasm and flushing. Carcinoid Crisis seems to be caused by a massive release of vasoactive substances, typically produced by neuroendocrine cells, and can emerge after abdominal procedures, but also spontaneously in rare instances. To date, there are no empirically derived guidelines for the management of this cancer-related medical emergency, and the available evidence essentially comes from single-case reports or dated small retrospective series. A transfer to the Intensive Care Unit may be necessary during the acute setting, when the severe hypotension becomes unresponsive to standard practices, such as volemic filling and the infusion of vasopressor therapy. The only effective strategy is represented by prevention. The administration of octreotide, anxiolytic and antihistaminic agents represents the current treatment approach to avoid hormone release and prevent major complications. However, no standard protocols are available, resulting in great variability in terms of schedules, doses, ways of administration and timing of prophylactic treatments.

show abstract

“…Carcinoid tumor is a rare, slow‐growing neuroendocrine tumor, which most commonly involves the gastrointestinal tract . Primary renal carcinoid tumors are extremely uncommon and renal failure associated with carcinoid syndrome is rare . Carcinoid tumor in a patient with end‐stage renal disease (ESRD) has not been reported.…”

Section: Introductionmentioning

confidence: 99%

“…2 Primary renal carcinoid tumors are extremely uncommon 2 and renal failure associated with carcinoid syndrome is rare. 3 Carcinoid tumor in a patient with endstage renal disease (ESRD) has not been reported. Penile necrosis in the form of dry gangrene in ESRD is a rare but devastating condition that usually has a grim prognosis.…”

Section: Introductionmentioning

confidence: 99%

A maintenance hemodialysis diabetic patient with unexplained pulmonary and gastrointestinal involvement

Yuvaraj

Abraham

Kurien

et al. 2015

Hemodialysis International

View full text Add to dashboard Cite

A 50-year-old man with diabetes mellitus with diabetic retinopathy, peripheral neuropathy, hypertension, and end-stage renal disease on maintenance hemodialysis, presented with persistent cough and hiccups, continued to be unwell with weight loss, poor appetite, and recurrent respiratory symptoms such as wheezing and cough. Whole body positron emission tomography-computed tomography scan showed metabolically active lesions in liver, stomach/lesser sac, pancreas, and left sixth rib. As he had repeated bilateral transudative pleural effusion, left mini thoracotomy with pleural biopsy showed no evidence of granuloma or malignancy. Upper gastroscopy showed tiny gastric polyp; biopsy revealed benign lesion. Left posterior rib biopsy from the lesion and iliac crest biopsy showed no evidence of malignancy or granuloma. Further evaluation showed plasma chromogranin A -5737 μg/L (<100 μg/L) with a repeat value of 6950 μg/L (<100 μg/L). He was initiated on oral sunitinib 25 mg once a day and injection octreotide 20 mg subcutaneously once a month. The plasma chromogranin A level and his symptoms, however, showed an initial improvement, but gradually worsened after 4 months despite being on treatment. After 6 months, the patient developed a gangrenous lesion of his glans penis with necrosis. Due to severe pain on conservative measures, penectomy with perineal urethrostomy was performed. Biopsy of the lesion showed blood vessels with intimal calcifications and thrombosis suggesting penile necrosis.

show abstract

Acute renal failure associated with carcinoid crisis

Cited by 6 publications

References 2 publications

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency

A maintenance hemodialysis diabetic patient with unexplained pulmonary and gastrointestinal involvement

Contact Info

Product

Resources

About